Status:
UNKNOWN
Mannitol Use During Cadaveric Kidney Transplantation
Lead Sponsor:
Rabin Medical Center
Conditions:
Renal Dialysis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
We propose a placebo controlled randomized study on the use of mannitol as an agent to protect against delayed graft function, during the surgical procedure of kidney transplantation from a cadaver. P...
Detailed Description
This study is a prospective randomized double-blind placebo-controlled trial comparing renal function outcomes in patients undergoing cadaver donor renal transplant for end stage kidney failure. Patie...
Eligibility Criteria
Inclusion
- Age \>18 years
- Patients on the list of cadaveric donor kidney transplantation
Exclusion
- Allergy to mannitol
- Allergy to furosemide
- Combined major surgical cases that may include transplantation of another organ on the same time, such as liver.
- Severe congestive heart failure (ejection fraction \< 30%)
- Patients with coagulation disorders.
- Patients who are not able to sign an informed consent
Key Trial Info
Start Date :
February 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2022
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT04705402
Start Date
February 1 2022
End Date
February 1 2022
Last Update
January 22 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.